Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus‑32 brachytherapy
-
Jie Ma [3] ; Gan Gao [3] ; Tao Chen [1] ; Jianning Zhang [2] ; Weidong Cao [2] ; Xinguang Yu [2] ; Hongwei Wang [2]
-
[1] Zhejiang University
Zhejiang University
China
-
[2] Chinese PLA General Hospital
Chinese PLA General Hospital
China
-
[3] PLA Medical School, Beijing 100853, People’s Republic of China
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 9, 2024, págs. 2198-2204
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Background Managing residual and recurrent craniopharyngioma effectively is crucial for improving patient outcomes. This study evaluates the combined use of gamma knife and phosphorus-32 brachytherapy, offering insights into alternative, less invasive treatment strategies.
Methods We conducted a retrospective analysis of 97 patients treated from 2010 to 2016 for residual and recurrent craniopharyngioma using gamma knife and phosphorus-32 brachytherapy. We classified these patients into three groups: superficial solid (Group A), simple cystic (Group B), and mixed cystic-solid (Group C). We assessed the treatment’s effectiveness by the tumor control rates and evaluated safety by monitoring vision, endocrine function improvements, and complication rates.
Results The treatment achieved complete and adequate control rates of 49.5% and 87.6%, respectively. We observed improvements in vision or visual fields in 55.1% of the patients. The morbidity rate was 15.5%. The study found no significant differences in tumor control rates among the various lesion types.
Conclusion The combination of gamma knife and phosphorus-32 brachytherapy presents a viable, minimally invasive alternative for treating residual and recurrent craniopharyngioma. It offers high tumor control and functional improvement rates, suggesting its potential as a preferred strategy in some instances.
